Search results
Results from the WOW.Com Content Network
In a study of more than 50,000 patients in the Mayo Clinic Health System https://bit.ly/37Btmhf, researchers found the effectiveness of Moderna's vaccine against infection had dropped to 76% in ...
Moderna's vaccine was approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older, but with a label indicating the shot was 79% effective at preventing ...
Last year, Moderna completed a Phase I/II clinical trial of an investigational influenza vaccine called mRNA-1018, which was tested against H5 and H7 bird flu subtypes.
It provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus. [ 42 ] [ 2 ] [ 22 ] [ 14 ] It is designed to be administered in two or three 0.5- mL doses given by intramuscular injection , primarily into the deltoid muscle, at an interval of at least 28 days apart.
Moderna Pfizer–BioNTech Moderna Days 0 and 28 Days 0 and 112 Phase II (1,200) [339] May 2021 – Mar 2023, Canada: Pfizer–BioNTech Moderna Pfizer–BioNTech Moderna Days 0 and 42 Phase II (400) [340] May 2021 – Jan 2022, France: Oxford–AstraZeneca Pfizer–BioNTech Days 0 and 28 Days 0 and 21–49 Phase II (3,000) [341] May–Dec 2021 ...
The company is also working on therapeutics for such issues as heart failure and Chikungunya, another mosquito-borne virus.This may be the first look you’ve taken inside Moderna, but it will ...
In May 2024, the mRNA vaccine Mresvia was approved for medical use in the United States by the US Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older, [31] [32] the third RSV vaccine approved in the United States.
Herpes simplex 2, the virus usually responsible for genital herpes, can cause oral herpes infections, too—you might imagine how. Once infected with oral herpes, most people show no symptoms ...